Polyol-interferon- b conjugate, method for the preparation thereof and pharmaceutical composition comprising thereof

PEG-IFN-b conjugate, in which PEG part is covalently bound to Cys17 of human IFN-b, are produced by method of site PEGylation with thiol-reactive PEGylating agent. Described is also a pharmaceutical composition for treating infections, tumors and autoimmune and inflammatory diseases. PEG-IFN-b konju...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ROBERTS MICHAEL J, SAWLIVICH WAYNE, EL TAYAR NABIL, HARRIS J. MILTON
Format:	Patent
Sprache:	eng ; slo
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PEG-IFN-b conjugate, in which PEG part is covalently bound to Cys17 of human IFN-b, are produced by method of site PEGylation with thiol-reactive PEGylating agent. Described is also a pharmaceutical composition for treating infections, tumors and autoimmune and inflammatory diseases. PEG-IFN-b konjugáty, v ktorých je PEG časť kovalentne naviazaná na Cys17 ľudského IFN-b, sú vyrábané spôsobom miestne špecifickej PEGylácie s tiolreaktívnym PEGylačným činidlom. Opísaný je aj farmaceutický prostriedok na liečenie infekcií, nádorov aautoimunitných a zápalových ochorení.